Current Clinical Experience and New Therapeutic Directions for Second-line and Subsequent Lines of Therapy in Metastatic Urothelial Carcinoma

Download this slideset from Matthew Milowsky, MD to review optimal treatment selection for patients with urothelial carcinoma and progression disease after previous therapy.
Matthew I. Milowsky, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.00 MB
Released: June 22, 2020

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

Supported by an independent educational grant from Merck & Co., Inc.

Supported by educational grants from
Astellas and Seattle Genetics, Inc.
QED Therapeutics

Supported by an independent educational grant from Merck & Co., Inc.

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL

Renier J. Brentjens, MD, PhD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

Downloadable slides on current treatment landscape of patients with ovarian cancer from Clinical Care Options (CCO)

Bradley J. Monk, MD, FACS, FACOG Released: December 3, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue